Literature DB >> 11073765

Serological survey and active surveillance for La Crosse virus infections among children in Tennessee.

T F Jones1, P C Erwin, A S Craig, P Baker, K E Touhey, L E Patterson, W Schaffner.   

Abstract

In 1998 and 1999, we performed a serosurvey and active surveillance for La Crosse encephalitis at a children's hospital in eastern Tennessee. Fifteen cases of La Crosse encephalitis were confirmed. Only 5 (0.5%) of 1000 serum samples being tested at the state laboratory for other diseases had evidence of antibodies to La Crosse virus. These findings suggest that La Crosse virus is newly endemic to eastern Tennessee.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11073765     DOI: 10.1086/317458

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  5 in total

Review 1.  Emerging infectious diseases: the Bunyaviridae.

Authors:  Samantha S Soldan; Francisco González-Scarano
Journal:  J Neurovirol       Date:  2005-10       Impact factor: 2.643

2.  First isolation of La Crosse virus from naturally infected Aedes albopictus.

Authors:  R R Gerhardt; K L Gottfried; C S Apperson; B S Davis; P C Erwin; A B Smith; N A Panella; E E Powell; R S Nasci
Journal:  Emerg Infect Dis       Date:  2001 Sep-Oct       Impact factor: 6.883

Review 3.  Infectious encephalitis: Management without etiological diagnosis 48hours after onset.

Authors:  P Fillatre; Y Crabol; P Morand; L Piroth; J Honnorat; J P Stahl; M Lecuit
Journal:  Med Mal Infect       Date:  2017-03-15       Impact factor: 2.152

4.  Screening for Viral Nucleic Acids in the Cerebrospinal Fluid of Dogs With Central Nervous System Inflammation.

Authors:  Renee M Barber; Qiang Li; Jonathan M Levine; Susan J Ruone; Gwendolyn J Levine; Patrick Kenny; Suxiang Tong; Scott J Schatzberg
Journal:  Front Vet Sci       Date:  2022-03-24

5.  Assessing risk in focal arboviral infections: are we missing the big or little picture?

Authors:  Andrew D Haddow; Carl J Jones; Agricola Odoi
Journal:  PLoS One       Date:  2009-09-09       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.